EGFR-TKI inhibitor based on investigator's choice: clinical trials recruiting now

Fewer than 3 recruiting trials found.

1

Recruiting trials

7

Conditions studied

10

US states with sites

16

Countries

Phase breakdown

Phase 3 1

Conditions being studied

Condition	Trials
Advanced Non-Small-Cell Lung Cancer	1
EGFR P-Loop and Alpha C-Helix Compressing	1
EGFR PACC	1
EGFR Uncommon Mutations	1
Lung cancer	1
Metastatic Non-Small-Cell Lung Cancer	1
Non-Small-Cell Lung Cancer	1

Recruiting trials involving EGFR-TKI inhibitor based on investigator's choice

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations

Common questions

How many recruiting trials involve EGFR-TKI inhibitor based on investigator's choice?

1 recruiting trial across 7 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.